From Breakthrough to Blockbuster: The Business of Biotechnology
- ISBN-10
- 0195084004
- ISBN-13
- 9780195084009
- Category
- Biotechnology industries
- Pages
- 241
- Language
- English
- Published
- 2022
- Publisher
- Oxford University Press
- Authors
- Donald L. Drakeman, Lisa N. Drakeman, Nektarios Oraiopoulos
Description
"Beginning in the 1970s, several scientific breakthroughs promised to transform the creation of new medicines. As investors sought to capitalize on these Nobel Prize-winning discoveries, the biotech industry grew to thousands of small companies around the world. Each sought to emulate what the major pharmaceutical companies had been doing for a century or more, but without the advantages of scale, scope, experience, and massive resources. How could a large collection of small companies, most with fewer than 50 employees, compete in one of the world's most breathtakingly expensive and highly regulated industries? This book shows how biotech companies have met the challenge by creating nearly 40% more of the most important treatments for unmet medical needs. Moreover, they have done so with much lower overall costs. The book focuses on both the companies themselves and the broader biotech ecosystem that supports them. Its portrait of the crucial roles played by academic research, venture capital, contract research organizations, the capital markets, and pharmaceutical companies shows how a supportive environment enabled the entrepreneurial biotech industry to create novel medicines with unprecedented efficiency. In doing so, it also offers insights for any industry seeking to innovate in uncertain and ambiguous conditions. Looking to the future, it concludes that biomedical research will continue to be most effective in the hands of a large group of small companies as long as national healthcare policies allow the rest of the ecosystem to continue to thrive"--
Get the book
Other editions
-
- 2022-02-14
- - pages
- Ebook
- Oxford University Press
Similar books
-
Antibody Therapeutics: Product Development, Market Trends, and Strategic Issues
By John Morrow, Rathin DasAntibody Therapeutics: Product Development, Market Trends, and Strategic Issues
-
Theranos, Inc: Managing Risk in a High-flying Biotech Start-up
By James S. O'Rourke, Caitlin Kelley, Shareen LeeThe case describes how a start-up bio-tech company covered up failed quality control standards leading to an expose in the Wall Street Journal.
-
The International biotechnology directory 1989: products, companies, research and organizations
By Y. R. Alston, J. CoombsThe International biotechnology directory 1989: products, companies, research and organizations
-
The Good, the Bad and the Living Dead: Venture Capital Cases in the Healthcare Industry
By Albert J. HenryThe population of new pacemaker patients grew 15% each year, about 8% of them died, leaving a net gain of about 7% each ... CDI's management team hoped to stay on, and Raytel quickly negotiated a long-term employment contract with the ...
-
Antibody Therapeutics: Production, Clinical Trials, and Strategic Issues
By John Morrow, Rathin DasProvides an in-depth examination of the status, upheavals, and challenges in the manufacturing arena of antibodies, in particular, and the biotherapeutics market place in general.
-
Biotechnology Entrepreneurship
By Holger Patzelt, Lars Schweizer, Judith BehrensThis article reviews the literature on biotechnology entrepreneurship. First, at the regional level, we focus on innovation networks and biotechnology clusters.
-
2005 European Biotechnology VC Directory: European Venture Capital Companies and Contacts
2005 European Biotechnology VC Directory: European Venture Capital Companies and Contacts
-
Writing High-quality Standard Operating Procedures: A Practical Guide to Clear, Concise, and Correct Sops
By Atul MathurUnder the guidance of Atul Mathur, an engineer and a technical writer with over fifteen years of experience, you'll learn to identify the attributes of high-quality SOPs; create right content structure for SOPs; follow a systematic process ...
-
Bio1000, 1991-1992: World Biotechnology Company Directory
Bio1000, 1991-1992: World Biotechnology Company Directory
-
Career Opportunities in Clinical Drug Research
By Rebecca Jane AndersonThis book is an easy-to-follow handbook that introduces readers to entry-level clinical job opportunities and explains how to qualify for them, with a particular emphasis on how to gain clinical experience that a hiring manager will accept.